Clarivate is a leading global provider of transformative intelligence, and the question for the next twelve months is whether the company can convert the 0.7% organic subscription revenue growth, the 1.5% organic ACV growth, the Life Sciences Healthcare segment divestiture, the $200 million debt reduction in the first half of 2026, the reaffirmed 2026 financial outlook, the $221.7 million non-cash goodwill impairment charge, the 18.8% Adjusted diluted EPS growth in the first half of 2026, the disciplined cost management, and the AI innovation roadmap into the kind of transformative-intelligence and value-creation-plan operating leverage the company has been telegraphing. The Q2 2026 print was the cleanest test of that thesis, and the cleanest signal is that CEO Matti Shem Tov said "the Value Creation Plan continues to drive meaningful progress, as we execute against our strategic priorities and strengthen Clarivate's foundation for organic growth acceleration. During the quarter, we expanded organic recurring revenue, advanced our AI innovation roadmap, maintained disciplined cost management, and strengthened our balance sheet through deleveraging. Together, with the recently announced divestiture of the Life Sciences Healthcare segment, these actions are creating a more focused company with greater financial flexibility, a higher recurring revenue mix, and a clear path to deliver long-term value to shareholders." The strategic tension is the 5.5% total revenue decline against the 1.5% organic ACV growth and the 18.8% Adjusted diluted EPS growth in H1 2026, and the forward question is whether the Life Sciences Healthcare segment divestiture and the AI innovation roadmap can compound the organic recurring revenue growth into the reaffirmed 2026 financial outlook the company has been telegraphing.
The 0.7% organic subscription revenue growth and the 1.5% organic ACV growth are the cleanest read on the operating quality, and the Life Sciences Healthcare segment divestiture is the proof. The Q2 2026 organic ACV grew 1.5% compared to June 30, 2025, reflecting continued progress toward a more sustainable, subscription-led revenue base. The Q2 2026 organic subscription revenues increased 0.7%, primarily due to new sales.
The Q2 2026 total revenues of $587.3 million were down 5.5% year over year, primarily due to inorganic divestitures and disposals, the Q2 2026 net loss of $268.6 million or $0.42 per diluted share was driven by a $221.7 million non-cash goodwill impairment charge, the Q2 2026 adjusted net income of $123.1 million or $0.19 per diluted share, the Q2 2026 Adjusted EBITDA of $247.2 million, the H1 2026 total revenues of $1,172.8 million, the H1 2026 net loss of $308.8 million or $0.48 per diluted share, the H1 2026 adjusted net income of $242.4 million or $0.38 per diluted share, the H1 2026 Adjusted EBITDA of $488.4 million, the H1 2026 operating cash flow of $233.4 million, the H1 2026 free cash flow of $122.9 million, the $200 million H1 2026 debt reduction, the reaffirmed 2026 financial outlook, the AI innovation roadmap, the disciplined cost management, the strengthened balance sheet through deleveraging, the greater financial flexibility, the higher recurring revenue mix, the clear path to deliver long-term value to shareholders, the resilience of the business model, and the commitment to strengthening Clarivate's financial profile while maintaining the flexibility to invest in the highest-value growth opportunities anchor the print. The forward question is whether the Life Sciences Healthcare segment divestiture and the AI innovation roadmap can compound the organic recurring revenue growth into the reaffirmed 2026 financial outlook.